Our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results for adults living with both obesity and type 2 diabetes, including substantial weight loss and meaningful blood sugar reduction. These results, announced at the European Association for the Study of Diabetes, matter because obesity and type 2 diabetes often share common biology. Potential treatments like this could offer real, meaningful benefit to people navigating both conditions. See our press release at the link in bio. #EASD2026